Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting AKT for cancer therapy
Maryam Shariati, Funda Meric‐Bernstam
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 11, pp. 977-988
Open Access | Times Cited: 230

Showing 1-25 of 230 citing articles:

PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Rui Liu, Youwen Chen, Guangzhi Liu, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 9
Open Access | Times Cited: 615
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4363-4363
Open Access | Times Cited: 237
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Qingfang Li, Zhihui Li, Ting Luo, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 116
PI3K/Akt/mTOR signaling pathway in cancer stem cells
Mohsen Karami Fath, Menooa Ebrahimi, Ehsan Nourbakhsh, et al.
Pathology - Research and Practice (2022) Vol. 237, pp. 154010-154010
Closed Access | Times Cited: 94
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Motahareh Mortazavi, Fatemeh Moosavi, Miriam Martini, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 176, pp. 103749-103749
Closed Access | Times Cited: 80
Role of the PI3K/Akt signaling pathway in liver ischemia reperfusion injury: a narrative review
Mengqin Wang, Ji Zhang, Nianqiao Gong
Annals of Palliative Medicine (2021) Vol. 11, Iss. 2, pp. 806-817
Open Access | Times Cited: 65
Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements
Salima Akter, Md. Ataur Rahman, Mohammad Nazmul Hasan, et al.
Cells (2022) Vol. 11, Iss. 4, pp. 650-650
Open Access | Times Cited: 63
Lipid Metabolism and Cancer
Hui Cheng, Meng Wang, Jingjing Su, et al.
Life (2022) Vol. 12, Iss. 6, pp. 784-784
Open Access | Times Cited: 63
MPST deficiency promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via AKT
Jie Zhang, Li Cen, Xiaofen Zhang, et al.
Redox Biology (2022) Vol. 56, pp. 102469-102469
Open Access | Times Cited: 61
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5796-5796
Open Access | Times Cited: 60
Apoptosis Induction, a Sharp Edge of Berberine to Exert Anti-Cancer Effects, Focus on Breast, Lung, and Liver Cancer
Yi Zhun Zhu, Na Xie, Yilu Chai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 44
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Maria Antonietta Occhiuzzi, Gernando Lico, Giuseppina Ioele, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 114971-114971
Closed Access | Times Cited: 42
Ferulic Acid: A Review of Pharmacology, Toxicology, and Therapeutic Effects on Pulmonary Diseases
Yiman Zhai, Tingyu Wang, Yunmei Fu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8011-8011
Open Access | Times Cited: 37
The neuroprotective mechanisms of naringenin: Inhibition of apoptosis through the PI3K/AKT pathway after hypoxic-ischemic brain damage
Luyao Li, Zhen Lin, Junhui Yuan, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116941-116941
Closed Access | Times Cited: 37
Combination Therapy of Radiation and Hyperthermia, Focusing on the Synergistic Anti-Cancer Effects and Research Trends
Seeun Kwon, Sumin Jung, Seung Ho Baek
Antioxidants (2023) Vol. 12, Iss. 4, pp. 924-924
Open Access | Times Cited: 24
Blood-testis barrier: a review on regulators in maintaining cell junction integrity between Sertoli cells
Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan
Cell and Tissue Research (2024) Vol. 396, Iss. 2, pp. 157-175
Closed Access | Times Cited: 15
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
Alexa J. Luboff, David L. DeRemer
Annals of Pharmacotherapy (2024) Vol. 58, Iss. 12, pp. 1229-1237
Closed Access | Times Cited: 12
UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT
Wenzhi Du, Sheng Tu, Wenxiu Zhang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 4, pp. 1389-1409
Open Access | Times Cited: 11
The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Ayda Baghery Saghchy Khorasani, Nasim Hafezi, Mohammad‐Javad Sanaei, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 3
Closed Access | Times Cited: 10
Immunometabolism in cancer: basic mechanisms and new targeting strategy
Ranran Su, Yingying Shao, Manru Huang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Structural Requirements of Isoform-Specific Inhibitors of Akt: Implications in the Development of Effective Cancer Treatment Strategies
Tenzin Adon, Syamal D. Bhattacharya, SubbaRao V. Madhunapantula, et al.
European Journal of Medicinal Chemistry (2025), pp. 117334-117334
Closed Access | Times Cited: 1
The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics
Md. Tariqul Islam, Fangzhi Chen, Hanchun Chen
Archives of Biochemistry and Biophysics (2021) Vol. 701, pp. 108811-108811
Closed Access | Times Cited: 45
Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
Xufen Yu, Jia Xu, Ling Xie, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 18054-18081
Open Access | Times Cited: 43
Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
Wei Hou, Bryan Bridgeman, Greg Malnassy, et al.
Hepatology Communications (2022) Vol. 6, Iss. 7, pp. 1786-1802
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top